ArticleJournal of medical biochemistry2026
Serum Omentin-1 and CS846: Biomarkers for diagnosis and post-TKA functional outcomes in knee osteoarthritis.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To determine the synergistic diagnostic value of serum Omentin-1 and cartilage oligomeric matrix protein epitope CS846 (CS846) in knee osteoarthritis (KOA) and to explore their link to functional recovery following total knee arthroplasty (TKA), thereby contributing to improved early screening and prognostic strategies. Methods: Osmislili smo prospektivnu kohortnu studiju koja je obuhvatila 84 ispitanika (42 sa KOA i 42 zdrave kontrole). Tehnika enzimski povezanog imunosorbentnog testa (ELISA) korisćena je za merenje serumskog omentina-1, CS846 i inflamatornih indeksa (hs-CRP i ESR). ROC krive (Receiver Operating Characteristic) odredile su dijagno-stičku efikasnost, a za kombinovanu dijagnozu je uspostav-ljen logistički regresioni model. Funkcionalni ishodi, mereni WOMAC rezultatima, i status rehabilitacije su pregledani 6 meseci nakon operacije. Results: Analysis revealed reduced Omentin-1 and elevated CS846 in KOA patients versus controls. The diagnostic per-formance (AU C= 0.851) of the biomarker combination surpassed that of individual tests. Patients with KL1-2 grades exhibited elevated Omentin-1 but lower CS846 levels compared to those with KL3-4 grades (P< 0.05). An inverse correlation was observed between Omentin-1 and inflammatory markers (hs-CRP ESR), contrasting with the positive correlation for CS846. Post-treatment, poor recov-ery was associated with more pronounced decreases in Omentin-1 and increases in CS846 (P< 0.05). The COM-bined model effectively predicted suboptimal rehabilitation outcomes (AU C= 0.857). Conclusions: The synergistic use of serum Omentin-1 and CS846 biomarkers boosts early detection capability for KOA while accurately forecasting post-TKA functional out-comes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.